Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2016 - 2025)

Historic Other financing activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Q3 2025 value amounting to $209000.0.

  • Viridian Therapeutics, Inc.\DE's Other financing activities fell 9846.92% to $209000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.7 million, marking a year-over-year decrease of 19827.61%. This contributed to the annual value of $446000.0 for FY2022, which is N/A changed from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Other financing activities of $209000.0 as of Q3 2025, which was down 9846.92% from $207000.0 recorded in Q1 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Other financing activities peaked at $18.1 million during Q3 2022, and registered a low of -$24.1 million during Q4 2024.
  • Its 4-year average for Other financing activities is $78363.6, with a median of $209000.0 in 2025.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Other financing activities in the last 5 years was 449181.82% (2021), contrasted with its biggest fall of 24750.84% (2021).
  • Over the past 4 years, Viridian Therapeutics, Inc.\DE's Other financing activities (Quarter) stood at -$5.3 million in 2021, then crashed by 235.93% to -$17.7 million in 2022, then crashed by 36.34% to -$24.1 million in 2024, then surged by 100.87% to $209000.0 in 2025.
  • Its last three reported values are $209000.0 in Q3 2025, $207000.0 for Q1 2025, and -$24.1 million during Q4 2024.